Evaluating the Impact of AI on Drug Discovery and Clinical Transition

Abstract

Artificial intelligence (AI) is reshaping the medicament production by transfigure drug realization, optimizing evolution pipelines, and amplify clinical transitions. Traditional drug discovery is hindered by lofty attrition rates, long schedule, and escalating costs, and ameliorate clinical success rates, whereas AI-driven approaches leverage machine learning, deep neural matrix, and generative models to analyse vast abstracts, envision atomic properties, and design novel admixtures with unprecedented efficiency. These capabilities compress discovery cycles from years to months and intensify patient stratification and reconciling trial designs, contributing to up to 85% advancement rates in Phase I–III trials. AI’s integration into translational medicine bridges the gap between laboratory fact-finding and clinical application, facilitating biomarker discovery and personalized treatment strategies. Despite its life-changing potential, provocation remain in data quality, model interpretability, and regulatory validation, necessitating hybrid human-AI approaches. Breakthroughs such as AlphaFold’s protein structure prediction and generative adversarial webbing for de novo drug design have demonstrated corporeal acceleration, reducing discovery cycles from years to months. AI further strengthens translational panacea by integrating real-world evidence, biomarker discovery, and patient stratification, thereby improving clinical trial triumph rates and advancing individualize therapeutics. Applications span target identification, virtual screening, ADMET prediction, drug repurposing, and trial optimization, with ventures like Insilico Medicine, Benevolent AI, and Exscientia successfully advancing AI-designed molecules into clinical juncture. Despite these advances, challenges remain in data quality, model interpretability, and regulatory substantiate, underscoring the need for hybrid human-AI approaches. This review explores AI’s multifaceted role across drug discovery, repurposing, optimization, and clinical trials, highlighting actuality applications and future directions in simply drug innovation. Overall, AI represents a transformative force in pharmaceuticals, bridging the gap between laboratory research and clinical practice, while promising faster, safer, and more cost-effective therapeutic innovations.